JOHNSON MATTHEY INC. for JOHNSON MATTHEY INC.
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Natural Resources NAT
S. 1317 American Mineral Security Act, provisions relating to promotion of US mining and processing of critical minerals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Trade (domestic/foreign) TRD
United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Transportation TRA
Potential bill establishing a DOT grant program relating to national alternative-fueled vehicle charging/fuel corridors and a new commercial truck emissions demonstration program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Budget/Appropriations BUD
FY20 budget proposals, provisions relating to the funding of the EPA and delaying provisions of the 2015 Ozone NAAQS.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Taxation/Internal Revenue Code TAX
H.R. 88 (115), Taxpayer First Act of 2018, provisions relating to tax credits associated with alternative-fueled vehicles and related refueling infrastructure. H.R. 1027 and S. 343, Fairness to Every Driver Act, provisions relating to tax credits and highway user fees associated with alternative-fueled vehicles. Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 1288 Clean Energy for America Act, provisions relating to removing caps and extending alternative fuel tax credits.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Environment/Superfund ENV
EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978 Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. S. 92 Regulations from the Executive in Need of Scrutiny Act of 2019, provisions relating to regulatory reform of the Administrative Procedures Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Government Issues GOV
H.R. 1 For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. S. 1762 Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Pharmacy PHA
H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.